When was xarelto approved?

Xarelto (rivaroxaban) was first approved by the U.S. FDA in July 2011, for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation. It later received additional approvals in the following years for other indications (e.g., DVT prophylaxis after hip/knee replacement, treatment of DVT/PE, etc.). If you need the exact date for a specific indication or for another country, tell me which one.